Immunogenicity of a monovalent pandemic influenza A H1N1 vaccine in health-care workers of a university hospital in Japan

Microbiology and Immunology

Volumn 54, Issue 10, 2010, Pages 618-624

  Igari, Hidetoshi ^a   Segawa, Shunsuke ^a   Watanabe, Akira ^a   Suzuki, Akiko ^b   Watanabe, Mariko ^a   Sakurai, Takayuki ^b   Kuroda, Fuminobu ^b   Watanabe, Masaharu ^a   Tatsumi, Koichiro ^b   Nakayama, Mikio ^a,c   Nakayama, Toshinori ^b   Suzuki, Kazuo ^d   Sato, Takeyuki ^a  

^a CHIBA UNIVERSITY HOSPITAL   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d CHIBA UNIVERSITY   (Japan)

Author keywords

Health care workers; Immunogenicity; Influenza A H1N1; Vaccine

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS A H1N1 VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; CHILL; CLINICAL TRIAL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HEALTH CARE PERSONNEL; HOSPITAL INFECTION; HUMAN; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; JAPAN; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; PANDEMIC INFLUENZA; PHASE 3 CLINICAL TRIAL; SEROCONVERSION; SINGLE DRUG DOSE; SKIN REDNESS; SYSTEMIC DISEASE; UNIVERSITY HOSPITAL; URTICARIA;

ADULT; AGED; ANTIBODIES, VIRAL; FEMALE; HEALTH PERSONNEL; HOSPITALS, UNIVERSITY; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; JAPAN; MALE; MIDDLE AGED; PANDEMICS; PROSPECTIVE STUDIES; VACCINATION;

EID: 77957943867     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2010.00254.x     Document Type: Article

References (24)

1. Fiore A.E., Shay D.K., Broder K., Iskander J.K., Uyeki T.M., Mootrey G., Bresee J.S., Cox N.J. (2009) Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009Morbidity and Mortality Weekly Report Recommendations and Reports 58(RR-8): 1-52.
2. Greenberg M.E., Lai M.H., Hartel G.F.,Wichems C.H., Gittleson C., Bennet J., Dawson G., HuW., Leggio C.,Washington D., Basser R.L. (2009) Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 361(25): 2405-13.
3. Zhu F.C.,Wang H., Fang H.H., Yang J.G., Lin X.J., Liang X.F., Zhang X.F., Pan H.X.,Meng F.Y., Hu Y.M., LiuW.D., Li C.G., LiW., Zhang X., Hu J.M., PengW.B., Yang B.P., Xi P.,Wang H.Q., Zheng J.S. (2009) A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 361(25): 2414-23.
4. Liang X.F.,Wang H.Q.,Wang J.Z., Fang H.H.,Wu J., Zhu F.C., Li R.C., Xia S.L., Zhao Y.L., Li F.J., Yan S.H., YinW.D., An K., Feng D.J., Cui X.L., Qi F.C., Ju C.J., Zhang Y.H., Guo Z.J., Chen P.Y., Chen Z., Yan K.M.,Wang Y. (2010) Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 375(9708): 56-66.
5. Kendal A.P., Pereira M.S., Skehel J.J., eds. (1982) Concepts and Procedures for Laboratory based Influenza Surveillance. Atlanta: Centers for Disease Control.
6. Rowe T., Abernathy R.A., Hu-Primmer J., ThompsonW.W., Lu X., LimW., Fukuda K., Cox N.J., Katz J.M. (1999) Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J ClinMicrobiol 37(4): 937-43.
7. Englund J.A.,Walter E.B., Gbadebo A., Monto A.S., Zhu Y., Neuzil K.M. (2006) Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics 118(3): e579-85.
8. Neuzil K.M., Jackson L.A., Nelson J., Klimov A., Cox N., Bridges C.B., Dunn J., DeStefano F., Shay D. (2006) Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 194(8): 1032-9.
9. Parkman P.D., Hopps H.E., Rastogi S.C., Meyer H.M. Jr. (1977) Summary of clinical trials of influenza virus vaccines in adults. J Infect Dis 136(Suppl): S722-30.
10. Sencer D.J., Millar J.D. (2006) Reflections on the 1976 swine flu vaccination program. Emerg Infect Dis 12(1): 29-33.
11. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T.,Wolff M. (2006) Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 354(13): 1343-51.
12. Ferguson N.M., Cummings D.A., Fraser C., Cajka J.C., Cooley P.C., Burke D.S. (2006) Strategies for mitigating an influenza pandemic. Nature 442(7101): 448-52.
13. Stephenson I., Nicholson K.G., Glück R., Mischler R., Newman R.W., Palache A.M., Verlander N.Q.,Warburton F.,Wood J.M., Zambon M.C. (2003) Safety and antigenicity of whole virus and subunit influenza A/Hong Kong/1073/99 (H9N2) vaccine in healthy adults: phase I randomised trial. Lancet 362(9400): 1959-66.
14. Ikeno D., Kimachi K., Kino Y., Harada S., Yoshida K., Tochihara S., Itamura S., Odagiri T., Tashiro M., Okada K., Miyazaki C., Ueda K. (2010) Immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1, NIBRG-14) vaccine administered by intramuscular or subcutaneous injection. Microbiol Immunol 54(2): 81-8.
15. Jiang T., Li X., LiuW., YuM., Liu J., Yu X., Qin E., CaoW., Leng Q., Qin C. (2010) Serum antibody response to the novel Influenza A (H1N1) Virus in the elderly. Clin Infect Dis 50(2): 285-6.
16. Itoh Y., Shinya K., Kiso M.,Watanabe T., Sakoda Y., Hatta M., Muramoto Y., Tamura D., Sakai-Tagawa Y., Noda T., Sakabe S., Imai M., Hatta Y.,Watanabe S., Li C., Yamada S., Fujii K., Murakami S., Imai H., Kakugawa S., Ito M., Takano R., Iwatsuki-Horimoto K., Shimojima M., Horimoto T., Goto H., Takahashi K., Makino A., Ishigaki H., Nakayama M., Okamatsu M., Takahashi K.,Warshauer D., Shult PA., Saito R., Suzuki H., Furuta Y., Yamashita M., Mitamura K., Nakano K., Nakamura M., Brockman-Schneider R., Mitamura H., Yamazaki M., Sugaya N., Suresh M., Ozawa M., Neumann G., Gern J., Kida H., Ogasawara K., Kawaoka Y. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460(7258): 1021-5.
17. Hancock K., Veguilla V., Lu X., ZhongW., Butler E.N., Sun H., Liu F., Dong L., DeVos J.R., Gargiullo P.M., Brammer T.L., Cox N.J., Tumpey T.M., Katz J.M. (2009) Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.N Engl J Med 361(20): 1945-52.
18. Jain S., Kamimoto L., Bramley A.M., Schmitz A.M., Benoit S.R., Louie J., Sugerman D.E., Druckenmiller J.K., Ritger K.A., Chugh R., Jasuja S., Deutscher M., Chen S.,Walker J.D., Duchin J.S., Lett S., Soliva S.,Wells E.V., Swerdlow D., Uyeki T.M., Fiore A.E., Olsen S.J., Fry A.M., Bridges C.B., Finelli L. (2009) Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 20N Engl J Med 361(20): 1935-44.
19. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., Fukuda K. (2004) Influenza-associated hospitalizations in the United States. JAMA 292(11): 1333-40.
20. ThompsonW.W., Shay D.K.,Weintraub E., Brammer L., Cox N., Anderson L.J., Fukuda K. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289(2): 179-86.
21. Centers for Disease Control and Prevention. (2009) Novel influenza A (H1N1) virus infections among health-care personnel-United States, April-May 20Morbidity and Mortality Weekly Report 58: 641-5.
22. Murray S.B., Skull S.A. (2002) Poor health care worker vaccination coverage and knowledge of vaccination recommendations in a tertiary Australian hospital. Aust N Z J Public Health 26(1): 65-8.
23. Russell M.L., Henderson E.A. (2003) The measurement of influenza vaccine coverage among health care workers. Am J Infect Control 31(8): 457-61.
24. Hollmeyer H.G., Hayden F., Poland G., Buchholz U. (2009) Influenza vaccination of health care workers in hospitals-a review of studies on attitudes and predictors. Vaccine 27(30): 3935-44.